Leukemia, Lymphoma
Conditions
Keywords
pediatric, acute leukemia/lymphoma
Brief summary
The hypothesis of the study is that propofol-fentanyl sedation for lumbar punctures in children with acute leukemia/lymphoma results in fewer adverse events than propofol sedation alone. Secondary hypotheses state that propofol-fentanyl sedation results in a better sedation induction, recovery profile and is preferred by patients/families. The study is a double blind, randomized, placebo controlled crossover study. Following the induction phase of chemotherapy, children will be randomized in a crossover manner to receive either fentanyl-propofol or propofol-placebo for future lumbar punctures. Patients will be studied on two separate occasions, once with propofol-placebo (normal saline) and once with propofol-fentanyl. Children will be monitored continuously by pulse oximetry, electrocardiogram (ECG) and direct nursing and physician observation during the sedation in accordance with the University of Wisconsin (UW) Pediatric Policy and Procedure. Propofol will be titrated to a Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) score of ≤ 7 for all children. Oxygen saturation, respiratory rate, heart rate and blood pressure will be recorded every 3 minutes by a study investigator during sedation.
Interventions
DRUGPropofol alone
Sponsors
University of Wisconsin, Madison
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children ages 2 years to 18 years with acute leukemia/lymphoma cared for by physicians in the Division of Hematology/Oncology in the Department of Pediatrics and receiving sedation for diagnostic/therapeutic lumbar punctures (LPs) in the UW Pediatric Sedation Program * Enrollment will occur after the induction phase of chemotherapy.
Exclusion criteria
* American Society of Anesthesiology score ≥ 3 * Cardiorespiratory instability * Allergy to propofol or its components * Age less than 2 years * Patients receiving other sedative analgesics * Patients with an oxygen requirement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fewer adverse cardiorespiratory events defined as oxygen desaturations and hypotension | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient/family preference, ease of induction, and recovery pattern | — |
Countries
United States
Outcome results
None listed